Companies / Singapore
India's Strides Buys Into Generics
September 2006 | Company Finance AlertFast-expanding Indian generic drugmaker Strides Arcolab is to acquire Singapore's leading manufacturer of off-patent medicines, Drug Houses of Australia (DHA). The value of deal - which will see local conglomerate Haw Par exit the generics sector - is valued at US$19.7mn. DHA operates a manufacturing unit in Jurong, and also markets its products in Malaysia, Hong Kong and
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
